N@N

PRO, DRRX, ARQL, SNTA, KRG, TACT Expected To Be Up After Next Earnings Releases

May 4, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 5th 2011 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and 6 Consecutive Days earnings reports. PROS HOLDINGS INC (NYSE:PRO), DURECT CORPORATION (NASDAQ:DRRX), ARQULE INC (NASDAQ:ARQL), SYNTA PHARMACEUTICALS CORP (NASDAQ:SNTA), KITE REALTY GROUP TRUST (NYSE:KRG), TRANSACT TECHNOLOGIES INC (NASDAQ:TACT) are all expected to be Up After their earnings are released Thursday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Up After earnings are released Thursday:

     Symbol     Company                             # of Reports            Quarter     Release Time
     PRO        PROS HOLDINGS INC                   6 Quarter               Q1          After
     DRRX       DURECT CORPORATION                  6 Quarter               Q1          After
     ARQL       ARQULE INC                          6 Quarter               Q1          Before
     SNTA       SYNTA PHARMACEUTICALS CORP          6 Quarter               Q1          Before
     KRG        KITE REALTY GROUP TRUST             6 Quarter               Q1          After
     TACT       TRANSACT TECHNOLOGIES INC           6 Quarter               Q1          After

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

PROS HOLDINGS INC (NYSE:PRO) - PROS Holdings, Inc. provides pricing and margin optimization software worldwide. It offers PROS Pricing Solution Suite, which is a set of integrated software products that enables enterprises to apply pricing science to determine, analyze, and execute optimal pricing strategies. The companys software products support pricing decisions through the aggregation and analysis of enterprise application data, transactional data, and market information. Its PROS Pricing Solution Suite consists of Scientific Analytics, Price Optimizer, and Deal Optimizer. The Scientific Analytics software product provides visibility into pricing data and performance across the different segments of a business, which helps companies understand the pocket margin and its components, and locate detrimental pricing trends and underperforming segments of their businesses. The Price Optimizer software product help companies set and implement pricing policies throughout an enterprise and improve execution through pricing decision and negotiation support. The Deal Optimizer software product offers companies with pricing-related predictive analytics to optimize their pricing decision-making at the time of the sales transaction. The company also offers pricing and implementation professional services, as well as ongoing support and maintenance. PROS Holdings sells and markets its software products primarily through its direct sales force to customers in manufacturing, distribution, services, hotel and cruise, and airline industries. The company was founded in 1985 and is headquartered in Houston, Texas.

DURECT CORPORATION (NASDAQ:DRRX) - DURECT Corporation focuses on the development of pharmaceutical products for pain, central nervous system disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. Its products include Remoxy, an oxycodone gelatin capsule for chronic pain, which is accepted as a new drug application; POSIDUR, a release formulation of bupivacaine that is under Phase III clinical trial for post operative pain; ELADUR, a transdermal bupivacaine patch, which is under Phase II clinical trial, provides continuous delivery of bupivacaine for up to three days from a single application, as well as for the treatment of pain associated with post-herpetic neuralgia; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch, which is under Phase II clinical trial, provides continuous delivery of sufentanil for a period of up to seven days from a single application. The companys products also comprise oral controlled release opioid for pain that is under the Phase I clinical trial; and ORADUR-ADHD, a preclinical trial product targeting attention deficit hyperactivity disorder. It markets ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals. The company also develops and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. The company has strategic agreements with Alpharma Ireland Limited; Nycomed Danmark, ApS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Curaxis Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; NeuroSystec Corporation; and King Pharmaceuticals, Inc. DURECT Corporation was founded in 1998 and is based in Cupertino, California.

ARQULE INC (NASDAQ:ARQL) - ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development of B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

SYNTA PHARMACEUTICALS CORP (NASDAQ:SNTA) - Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its research and development programs include STA-9090, an Hsp90 inhibitor that is in Phase II stage for non-small cell lung cancer and gastrointestinal stromal tumors, as well as in Phase I for hematologic cancers and solid tumors; Elesclomol, an oxidative stress inducer that is in Phase I/II stage for solid and hematologic cancers; and STA-9584, a vascular disrupting agent, which is in preclinical development for cancer. The companys programs also include Apilimod (STA-5326), an oral IL-12/23 inhibitor, which is in Phase IIa stage for rheumatoid arthritis; and Oral CRACMchannelinhibitor that is in preclinical development for autoimmune diseases and respiratory conditions. It has a partnership with Hoffmann-La Roche for the development of CRACM inhibitors; and a joint collaboration with The Multiple Myeloma Research Foundation Inc. for the clinical development of ganetespib in patients with multiple myeloma. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

KITE REALTY GROUP TRUST (NYSE:KRG) - Kite Realty Group Trust, a real estate investment trust (REIT), engages in the acquisition, development, expansion, construction, ownership, leasing, operation, and management of neighborhood and community shopping centers, and commercial real estate properties in the United States. It also provides real estate facility management, construction, development, and other advisory services to third parties. As of March 31, 2008, the company owned interests in 57 operating properties consisting of 52 retail properties, 4 commercial properties, and 1 associated parking garage, as well as had 10 properties under development or redevelopment. Kite Realty Group qualifies as a REIT under the Internal Revenue Code. As a REIT, the company would not be subject to federal tax to the extent that it distributes at least 90% of its taxable income to its shareholders. Kite Realty Group was founded in 1968 and is based in Indianapolis, Indiana.

TRANSACT TECHNOLOGIES INC (NASDAQ:TACT) - TransAct Technologies Incorporated engages in the design, development, assembly, and marketing of transaction printers and printer-related services, supplies, and spare parts. It provides thermal, inkjet, and impact printers to print various transaction records, such as receipts, tickets, coupons, register journals, and other documents used in the casino, gaming, lottery, banking, kiosk, and point-of-sale industries. The company also offers various supplies and consumables products, such as inkjet cartridges, ribbons, receipt paper, and other transaction supplies used in the printing and scanning activities in the hospitality, banking, retail, gaming, and government markets, as well as provides replacement parts and maintenance services. TransAct Technologies Incorporated distributes its products under the Epic and Ithaca brand names through original equipment manufacturers, value-added resellers, distributors, telephone sales, and its online Webstore, as well as directly to end-users in the Americas, Europe, the Middle East, Africa, Asia, Australia, the Caribbean Islands, and the South Pacific. The company was founded in 1996 and is headquartered in Hamden, Connecticut.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641